NASDAQ:OHRP OHR Pharmaceutical Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OHR Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.27 -0.66 (-6.65 %) (As of 03/2/2021 12:00 AM ET) Add Compare Share Today's Range$9.23Now: $9.27▼$9.9350-Day Range$5.39MA: $7.37▼$9.0752-Week Range$1.60Now: $9.27▼$6.28Volume110,723 shsAverage Volume180,228 shsMarket Capitalization$26.22 millionP/E RatioN/ADividend YieldN/ABeta0.84 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.Read More HeadlinesEOM Pharmaceuticals Appoints Business Veteran Wayne I. Danson as Chief Financial Officer and TreasurerDecember 19, 2020 | benzinga.comBoot Barn Holdings (BOOT)November 14, 2020 | forbes.comOppenheimer: These 2 Stocks Could Double, If Not MoreOctober 20, 2020 | finance.yahoo.comMedical Device Innovation Continues to Transform Future of Healthcare SectorSeptember 15, 2020 | bloomberg.comNeuBase (NBSE) in Focus: Stock Moves 5.6% HigherJune 15, 2020 | finance.yahoo.comOhr Pharmaceutical (OHRP) Stock Climbs on Positive Retinal Vein Occlusion Phase II Study ResultsNovember 23, 2019 | www.thestreet.comOhr Pharma and NeuBase complete mergerJuly 12, 2019 | seekingalpha.comNeuBase Therapeutics Closes Merger Transaction with Ohr PharmaceuticalJuly 12, 2019 | finance.yahoo.comNeubase TherapeuticsJuly 10, 2019 | www.benzinga.comOhr Pharmaceutical Merger With Neubase Therapeutics Approved By ShareholdersJuly 10, 2019 | www.benzinga.comOhr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc.July 10, 2019 | finance.yahoo.comOhr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019July 3, 2019 | finance.yahoo.comSee More Headlines Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OHRP Previous Symbol CUSIPN/A CIK1173281 Webwww.ohrpharmaceutical.com Phone212-682-8452Employees3Year FoundedN/ADebt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.86 per share Price / Book2.40Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-13,230,000.00 Net MarginsN/A Return on Equity-75.46% Return on Assets-71.18% Miscellaneous Outstanding Shares2,829,000Market Cap$26.22 million Next Earnings DateN/A OptionableOptionable MarketRank™Overall MarketRank™0.56 out of 5 starsMedical Sector1396th out of 1,969 stocksPharmaceutical Preparations Industry614th out of 772 stocksAnalyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for OHR Pharmaceutical. Previous Next 2.8 Community Rank Outperform VotesOHR Pharmaceutical has received 295 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOHR Pharmaceutical has received 228 “underperform” votes. (Add your “underperform” vote.)Community SentimentOHR Pharmaceutical has received 56.41% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote “Outperform” if you believe OHRP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOHR Pharmaceutical does not currently pay a dividend.Dividend GrowthOHR Pharmaceutical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OHR Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.50% of the stock of OHR Pharmaceutical is held by insiders.Percentage Held by InstitutionsOnly 10.70% of the stock of OHR Pharmaceutical is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioOHR Pharmaceutical has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Receive OHRP News and Ratings via Email Sign-up to receive the latest news and ratings for OHRP and its competitors with MarketBeat's FREE daily newsletter. OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions What stocks does MarketBeat like better than OHR Pharmaceutical? Wall Street analysts have given OHR Pharmaceutical a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OHR Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were OHR Pharmaceutical's earnings last quarter? OHR Pharmaceutical Inc (NASDAQ:OHRP) posted its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. View OHR Pharmaceutical's earnings history. When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work? OHR Pharmaceutical's stock reverse split before market open on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of OHR Pharmaceutical stock prior to the reverse split would have 5 shares after the split. Who are OHR Pharmaceutical's key executives? OHR Pharmaceutical's management team includes the following people: Dr. Jason Scott Slakter, CEO, Pres & Director (Age 61)Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 35)Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 55)Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs Who are some of OHR Pharmaceutical's key competitors? Some companies that are related to OHR Pharmaceutical include Helix BioPharma (HBPCF), Avenue Therapeutics (ATXI), Diffusion Pharmaceuticals (DFFN), BetterLife Pharma (PVOTF), SCYNEXIS (SCYX), Kazia Therapeutics (KZIA), Sunesis Pharmaceuticals (SNSS), Merrimack Pharmaceuticals (MACK), Savara (SVRA), Entasis Therapeutics (ETTX), AgeX Therapeutics (AGE), Vascular Biogenics (VBLT), PDS Biotechnology (PDSB), Advaxis (ADXS) and Stealth BioTherapeutics (MITO). View all of OHRP's competitors. What other stocks do shareholders of OHR Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), IVERIC bio (OPHT), Novavax (NVAX), Immunomedics (IMMU), OPKO Health (OPK), Dynavax Technologies (DVAX) and Energy Transfer (ET). What is OHR Pharmaceutical's stock symbol? OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP." What is OHR Pharmaceutical's stock price today? One share of OHRP stock can currently be purchased for approximately $9.27. How much money does OHR Pharmaceutical make? OHR Pharmaceutical has a market capitalization of $26.22 million. How many employees does OHR Pharmaceutical have? OHR Pharmaceutical employs 3 workers across the globe. What is OHR Pharmaceutical's official website? The official website for OHR Pharmaceutical is www.ohrpharmaceutical.com. Where are OHR Pharmaceutical's headquarters? OHR Pharmaceutical is headquartered at 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. How can I contact OHR Pharmaceutical? OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected] This page was last updated on 3/3/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
